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Purpose: Some patient subsets are at higher risk of sleep apnea, including patients with chronic 
pain. However, it is unclear whether patients and their caregivers are aware of the possibly 
increased risk of sleep apnea in this population. Chronic pain is often treated with opioids which 
may decrease both the central respiratory drive and the patency of the upper airway, potentially 
contributing to this sleep disorder. Using a self-reporting questionnaire approach in the chronic 
pain population, this study surveyed patient and caregiver awareness surrounding the risk of sleep 
apnea. In addition, we looked at the influence of opioid therapy on the prevalence of sleep apnea.
Participants and methods: Consecutive patients presenting to a pain clinic were invited to 
participate anonymously in a survey that included the STOP-Bang sleep apnea questionnaire, 
which assesses patients’ knowledge, testing, diagnosis, or treatment of sleep apnea and whether 
their caregivers had discussed with them their increased risk of sleep apnea and opioid use.
Results: Among 305 participating patients, 58.2% (n=173) screened positive for sleep apnea. 
Among the 202 patients on opioid therapy, 59.2% (116/202) were STOP-Bang positive (score 
≥3). However, only 37.5% (n=72/173) of these patients had discussed their risk of sleep apnea 
with a caregiver and only 30.7% (n=59) underwent testing. Against expectation, opioids did 
not increase the prevalence of sleep apnea in our study population.
Conclusion: Chronic pain patients had a high risk of sleep apnea, regardless of opioid prescrip-
tion. Most patients were unaware of their increased risk and denied undergoing the necessary 
testing. Greater attention to screening, testing, and education for sleep apnea needs to be paid 
in chronic pain patients, especially given the potentially dangerous ramifications of opioid-
induced sleep apnea.
Keywords: sleep apnea, opioids, narcotics, STOP-Bang survey
Introduction
An estimated 100 million Americans suffer from chronic pain disorders.1 This number 
includes patients with cancer and non-cancer pain. In the latter group, chronic non-
cancer pain (CNCP) patients can suffer from a wide variety of painful conditions such 
as fibromyalgia, arthritis, and other inflammatory conditions, afflicting primarily an 
older demographic.
Sleep apnea affects 2%–14% in community-screened normal populations, but has 
a much higher prevalence in certain patient subgroups.2 Twenty to 90% of individuals 
referred for sleep studies, a physician-selected cohort, are affected by sleep apnea.2,3 
Males are three times more likely to experience sleep apnea.4 Further, the prevalence 
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increases with age, especially in people more than 60 years 
old, and with obesity.3,4
Sleep-disordered breathing has two major manifesta-
tions, central sleep apnea (CSA) or obstructive sleep apnea 
(OSA). Hence, sleep apnea may be a consequence of central 
depression of respiratory rate, amplitude, reflex responses, 
and reduced brain arousability, as well as the function of 
chemoreceptors that monitor changes in blood oxygen and 
carbon dioxide levels.5 Alternatively, sleep apnea is due 
to obstruction by soft tissues of the upper airway.6 Sleep-
disordered breathing is associated with an increased risk 
for cardiovascular and cerebrovascular disease, as well as 
a multitude of other morbidities. Patients with untreated 
sleep-disordered breathing have a higher mortality risk, 
independent of age, gender, and body mass index (BMI).7
Pain causes sleep disorders such as wakefulness and sleep 
apnea. There is a relationship between pain and sleep distur-
bances.8,9 Over 70% of patients with chronic pain disorders 
report sleep disruption, and lack of restful sleep increases 
hyperalgesia.8,9 By contrast, sleep rebound, especially in 
non-REM sleep may have an analgesic effect.9 Hence, pain 
induces sleep disorders and lack of sleep increases pain.
Opioids are widely used to treat chronic pain. In 1986 
Portenoy and Foley published a review of 38 cases of CNCP 
patients successfully treated with opioids,10 leading to wider 
use in the management of CNCP. Today, it is ethically man-
dated to treat CNCP,11 resulting in a four-fold increase in opi-
oid prescription during the 2000–2010 period. Unfortunately, 
accidental opioid overdose, death, and dependency have 
increased dramatically,12 reaching “epidemic” proportions13,14 
and prescription opioids for chronic pain are recognized as 
one of the roots of this problem.15,16
Opioid medications cause numerous unwanted and adverse 
effects, apart from overdose. Of note, opioids have been shown 
to decrease both central respiratory drive and the patency of the 
upper airway. Hence, sleep-disordered breathing is observed in 
patients on chronic opioid therapy. An observational study of 
chronic pain patients on opioid therapy who received overnight 
polysomnograms demonstrated an abnormal apnea-hypopnea 
index (≥5 per hour) in 75% of patients, with a mixture of both 
central and obstructive apneas.8 A dose-dependent relationship 
between chronic opioid use and the development of a peculiar 
pattern of respiration, consisting of central apneas and ataxic 
breathing, has also been shown.17 Patients receiving sustained-
release opioid medications have respiratory abnormalities 
which are unique compared to opioid-free patients with OSA. 
Longer, more severe hypoxia was observed in NREM com-
pared to REM sleep. During NREM sleep, irregular respiratory 
pauses and gasping without periodicity were present. Nasal 
positive airway pressure (CPAP) was shown to be ineffective 
in these patients.18
Proper identification of chronic pain patients at a higher 
risk for sleep-disordered breathing may be a difficult task 
to accomplish due to the sedative effects of opioid medica-
tions, which overlap with vague symptoms of sleep apnea. 
Screening questionnaires have been developed to identify 
individuals at a higher risk for sleep apnea, including the 
checklist of the American Society of Anesthesiology, the 
STOP questionnaire (snoring, tiredness, observed apnea, 
and high blood pressure), the STOP-Bang questionnaire 
(STOP plus BMI, age, neck circumference, gender), and the 
Epworth Sleepiness Scale. The STOP-Bang questionnaire is 
a concise and easy-to-use, eight point, dichotomized (yes/
no) screening tool.19 In a systematic review of screening 
questionnaires for sleep apnea, the STOP-Bang questionnaire 
had the highest methodological quality and sensitivity.20 It 
has been validated in different populations, including surgical 
patients,21 hospitalized patients,22 and patients presenting to 
a sleep disorders unit.23
The medical literature is limited in terms of the methods 
used for the screening of patients on chronic opioids for sleep 
apnea. Chronic opioid users’ awareness of their increased 
risk for sleep apnea is also unknown. It is important to 
identify those chronic pain patients who have sleep apnea, 
so that early treatment can be initiated in order to improve 
their quality of life and health status. The aims of this study 
were to: 1) investigate risk of sleep apnea in the chronic 
pain population, 2) assess knowledge and awareness of risk 
for sleep apnea in patients, 3) evaluate the discussion and 
assessment of sleep-disordered breathing with physicians as 
a measure of their awareness, and 4) determine whether the 
use of opioids increases the prevalence of sleep apnea in the 
chronic pain population. This study was also intended to bring 
to the attention of the sleep and pain medicine communities, 
as well as general medical practitioners, the extent to which 
sleep apnea may be under-diagnosed and under-treated in 
the chronic pain population.
Participants and methods
Participants
The University of California Davis Pain Management Clinic 
provides cutting-edge treatment of significant chronic pain 
through a multidisciplinary approach. The clinical team 
includes anesthesiologists, internists, and psychiatrists 
with expertise in pain management to restore function and 
decrease pain.
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The study protocol was approved by the UC Davis Insti-
tutional Review Board (IRB number 637877–1). The study 
population was recruited from 357 consecutive patients pre-
senting for their scheduled consultation at the Pain Manage-
ment Clinic between September 9 and December 23, 2014. 
Patients were invited to participate in an anonymous survey. 
Subjects were excluded from the study if they declined to 
participate or were under 18 years of age. Of the 357 patients 
who were invited to participate, 305 met the inclusion criteria. 
Most of the patients attending this specialist consultation 
clinic who were on opioid therapy received their prescriptions 
from external community providers, such as their primary 
care physicians.
Procedure
All survey and questionnaire data collected were self-reported 
by patients and considered anonymous. Thus, confirmation 
of the disease status and medication relied on self-report. 
Patients were asked to complete the survey on their own, 
while waiting for their physician in treatment rooms. 
Measures
The survey comprised eight pages and included diagnosis of 
pain disorder (yes, no), consumption of narcotic pain medica-
tion including type and duration, and a detailed sleep history 
(Supplementary material). The survey also included stan-
dardized validated questionnaires related to sleepiness and 
sleep-disordered breathing. We also noted whether patients 
reported having knowledge of sleep apnea, whether they had 
discussed sleep apnea with a health care professional, and if 
they had been tested for, diagnosed with or treated for sleep 
apnea. Completion took approximately 5 minutes.
The STOP-Bang questionnaire, described in detail 
elsewhere (http://www.stopbang.ca/osa/screening.php) is 
comprised of eight yes/no questions relating to the risk 
factors for OSA. Questions include snoring, daytime tired-
ness, observed apneas, high blood pressure, BMI (greater 
than 35 kg/m2), age (greater than or equal to 50 years), neck 
circumference (greater than 40 cm), and gender (male). 
Measurement of height and weight, and the online calcula-
tion of BMI, were performed by the registered nurses as part 
of the regular medical visit. A tape measure was included 
in the survey, with instructions and anatomical guidelines 
for measuring neck circumference. A trained research 
assistant was present to assist with the neck circumference 
measurement. A patient was considered at risk for OSA if 
they had three or more positive responses on the STOP-
Bang questionnaire.19
The Epworth Sleepiness Scale (http://epworthsleepi-
nessscale.com/about-the-ess/) is used to measure daytime 
sleepiness by assessing the patient’s likelihood of falling 
asleep under eight common scenarios. Likelihood is scored 
between 0 (never) and 3 (high chance) with a total score 
out of 24. A score greater than 10 is indicative of excessive 
daytime sleepiness.24
Statistical analysis
Chi-squared test was used to study the association between 
two categorical variables. A P-value <0.05 was considered 
statistically significant. All analyses were performed with 
SAS v9.4 (SAS Institute Inc., Cary, NC, USA).
Results
Our study population had a mean age of 57.5+13.9 years. 
The majority were female (66.1%) and Caucasian (81.2%) 
(Table 1). The majority of the participants (72.2%) were 
overweight or obese (BMI ≥25) (Table 1). Ninety-one point 
nine percent (n=274) of the entire cohort was diagnosed 
with a pain disorder of 6 months or longer. There were 202 
(66.5%) patients on narcotic pain medication. Of the patients 
who reported on their length of narcotic use, 75.7% (n=131) 
of them were using narcotic pain medication for 6 months 
or longer.
Table 2 reports on the prevalence of sleep apnea in pain 
patients, and their awareness of it. According to the STOP-
Bang assessment, overall 58.3% were positive (score ≥3) for 
sleep apnea. There was no difference in prevalence between 
opioid-treated and untreated patients. Most patients (90.7%) 
were knowledgeable about sleep apnea, and this percentage 
was not different in the opioid and non-opioid subgroups. 
However, only approximately a third (35.9%) of all patients 
had discussed their risk of sleep apnea with a health care 
provider, and this was true even in the patients using opioids 
who are at a theoretically greater risk. Furthermore, only 
29.0% had ever been tested for sleep apnea and only 22.7% 
of the whole of our chronic pain population had been treated.
A summary of outcomes for the Epworth Sleepiness 
Scale and the STOP-Bang score screening questionnaires 
is reported in Table 3. Among all subjects, 24.2% suffered 
excessive daytime sleepiness (Epworth Sleepiness Scale 
>10). Among opioid users, 25.9% (n=50) had an Epworth 
Sleepiness Scale score greater than 10, compared with 
22.2% (n=22) of the opioid non-users, a difference that 
was not significant (P=0.58). According to the STOP-Bang 
score, 58.3% were “positive” for sleep apnea with a score of 
≥3. However, there was no significant difference (P=0.82) 





Table 1 Demographic characteristics of opioid users and non-users



































Native Hawaiian or Pacific Islander
american indian or alaskan Native

































healthy weight (BMi ≥18.5 and <25)




































Notes: Not all participants answered all questions. The number of respondents (*) in each section are shown. Missing answers are given as “not known” in the table. P, 
significance of difference between opioid and non-opioid users.
Abbreviation: NS, not significant.
between the STOP-Bang score of ≥3 in opioid users (59.2%) 
and non-users (56.4%). In fact, there was no difference in 
STOP-Bang score at any level between opioid users and 
non-users (P=0.84).
Figure 1 depicts the use of different opioid medica-
tions amongst our study population. The majority of our 
subjects were either taking hydrocodone (39.8%, n=121) or 
oxycodone (20.1%, n=61). The doses being taken were not 
recorded because of concern that patients’ recollection may 
be unreliable. Concomitant use of hypnotics was reported in 
24.7% (n=50) of opioid users, compared to 14.6% (n=14) of 
opioid non-users.
Some of the patients were taking hypnotic medications. 
The survey asked about use of hypnotic medications, but did 
not request the dose. Of the opioid users, 24.7% were taking a 
hypnotic while 14.6% of non-users were, too. This difference 
did achieve minimal statistical significance (P=0.046) but the 
frequency of OSA, according to the STOP-Bang score, did 
not differ in the patient groups using opioids vs those using 
opioids plus hypnotics.
Discussion
This survey found that a significant percentage of patients 
with CNCP are at risk for OSA. The proportion of CNCP 
patients screening positive on the STOP-Bang questionnaire 
for OSA is much higher than the prevalence reported in the 
general population. Given the relationship between chronic 
pain disorders and sleep disruption,8,9 it is understandable 
why almost 60% of our cohort screened at risk for sleep 
apnea using the STOP-Bang questionnaire. Remarkably, 
given the elevated risk associated with chronic pain, only 
approximately 35% of patients had discussed their apnea risk 
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Table 2 Patient awareness of sleep apnea risks





















































































Notes: None of the differences between groups were statistically significant by Chi-squared analysis. P-values ranged from 0.35 to 0.74. Not all participants answered all 
questions. The number of respondents (*) to each question is given.
Table 3 Summary of outcomes for epworth and STOP-Bang screening questionnaires
Screening questionnaire Opioid user group n=196 Opioid non-user group n=101 Total n=297
epworth Sleepiness Scale score – median (range) 7 (0–22) n=192* 7 (0–23) n=99* 7 (0–23) n=291*
epworth Scale score >10 (excessive daytime sleepiness) 50/192* (25.9%) 22/99* (22.2%) 72/291* (24.2%)
STOP-Bang score 0 3 (1.5%) 0 (0.0%) 3 (1.0%)
STOP-Bang score 1 24 (12.3%) 13 (12.9%) 37 (12.5%)
STOP-Bang score 2 53 (27.0%) 31 (30.7%) 84 (28.3%)
STOP-Bang score 3 49 (25.0%) 17 (16.8%) 66 (22.2%)
STOP-Bang score 4 29 (14.8%) 22 (21.8%) 51 (17.2%)
STOP-Bang score 5 19 (9.7%) 6 (5.9%) 25 (8.4%)
STOP-Bang score 6 14 (7.1%) 8 (7.9%) 22 (7.4%)
STOP-Bang score 7 4 (2.0%) 4 (4.0%) 8 (2.7%)
STOP-Bang score 8 1 (0.5%) 0 (0.0%) 1 (0.3%)
Notes: There were no statistically significant differences between the opioid user and non-user groups on the Epworth Sleepiness Scale (P=0.59) or for STOP-Bang positivity 
(P=0.84). *Not all participants answered all questions.
with their health care provider. The implication is that many 
of these individuals may be undiagnosed and unrecognized, 
supported by the fact that fewer than a quarter of our popu-
lation reported having been diagnosed and treated for sleep 
apnea by a physician. Although the screening questionnaires 
are not independently sufficient to make a clinical diagnosis, 
the discrepancy between the percentage screening at risk and 
the percentage reporting being diagnosed by a medical pro-
vider is striking. Given all of the health repercussions, such 
as cardiovascular and cerebrovascular disease, that come with 
a diagnosis of sleep apnea, special attention to the increased 
risk in the chronic pain population is warranted.
In recent years it has become common to treat chronic 
pain with opioids. However, opioid use is associated with 
substantial side effects and approximately 80% of individuals 
prescribed opioids will experience at least one side effect.25 
In addition, patients using opioids may suffer respiratory 
depression,26 endocrine effects, addiction, and fatal over-
dose. Paradoxically, patients may experience opioid-induced 
hyperalgesia27 with worsening pain in response to certain 
types of pain stimuli.
Opioids inhibit the basic sleep-wake mechanisms by 
inhibiting transmission through central cholinergic and 
adenosinergic pathways.28 In addition to central apnea, opi-





oids can contribute to OSA by deeply relaxing the tissues of 
the upper airway leading to mechanical obstruction.29 Sleep-
disordered breathing may increase the sensitivity of both 
central and airway effects of opioids, while sleep disruption, 
intermittent hypoxemia, and systemic inflammation influence 
pain behavior and sensitivity to opioids.30
Given the association between opioid treatment and sleep-
disordered breathing, it was expected that our CNCP patients 
using opioids would be at greater risk of sleep apnea. Against 
expectation, there was no difference in STOP-Bang positivity 
(score ≥3) between opioid users and non-users. This prompts 
the question whether opioids really do increase the risk of 
OSA in chronic pain patients, and whether the STOP-Bang 
questionnaire is appropriate to identify an increased risk for 
sleep apnea, in particular OSA, in opioid users. The choice 
and dose of opioid medication were “given to effect”. In 
hindsight, data collection of opioid dose as well as which 
medication, might have revealed a relationship between 
higher “morphine equivalent doses” and an increased fre-
quency of sleep-disordered breathing. If such a relationship 
were to exist, then a case could be made for mandatory 
sleep-disordered breathing screening in all patients taking 
high morphine equivalent doses (for example, exceeding 
200 mg/day).
One possibility is that there may be co-occurrence of 
central apnea and obstructive apnea with opioid use. The 
questions on the STOP-Bang questionnaire is useful in 
screening for obstructive sleep apnea rather than central sleep 
apnea. Indeed, these factors may well be absent in a person 
experiencing CSA. Therefore, the STOP-Bang questionnaire 
may not be the best instrument to identify increased total 
apnea risk due to opioid therapy. However, daytime sleepi-
ness which could be due to either central or peripheral apnea 
mechanisms, was the same in both opioid user and non-user 
patients. On the Epworth Sleepiness Scale, approximately 
25% of both opioid users and non-users scored >10 associ-
ated with “excessive daytime sleepiness”,24 perhaps suggest-
ing that there is not an excess of central apnea in the opioid 
using patients.
If the measures contributing to the STOP-Bang score 
were more prevalent in the non-opioid group, this might 
have hidden the effect of opioids on apnea. However, patient 
demographics were extremely similar in both the opioid and 
non-opioid user groups. Age, gender, and BMI, all known to 
be associated with OSA2–4 and addressed by the questions 
in the Bang section of the questionnaire, were not differ-
ent between opioid users and non-users (Table 1). There 
were no significant differences in any of these demographic 
parameters that might explain why the opioid user group 
did not have a higher proportion of patients with a positive 
STOP-Bang score.
Concomitant use of hypnotic medications such as ben-
zodiazepines has been shown to worsen sleep apnea. They 
have the potential to cause complete OSA in heavy snorers 
or short repetitive CSAs.31 When used in conjunction with 
opioid medications these effects can be even more pro-
nounced, making this a potentially lethal combination. In 

































































Figure 1 Opiate drug distribution among subjects.
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did not appear to increase the risk of OSA compared with 
use of opioids alone.
One possibility for the finding that the STOP-Bang ques-
tionnaire did not differentiate opioid users and non-users is 
that it did not distinguish the severity of apnea risk. In this 
study the STOP-Bang scores were dichotomized, by design, 
into positive or negative with a cut-off threshold score of ≥3. 
However, increasing STOP-Bang scores reportedly predict 
the probabilities from none through moderate to severe 
OSA.19 In this study cohort, the demographic data showed 
that the risk of OSA is high with older, overweight patients 
already scoring high on the Bang section of the question-
naire. An analysis of the STOP-Bang scores at all levels, 
from 0 to 8, showed no significant association with opioid 
use (Table 3), suggesting that the severity of OSA in opioid 
users is not greater than in opioid non-users.
Approximately one third of both the opioid-using and 
non-using patients had discussed the risk of sleep apnea with 
a health care provider. Fewer had been tested for sleep apnea. 
Overall, only approximately 20% of patients were diagnosed 
and treated for sleep apnea. These observations suggest a 
knowledge gap in patients being prescribed opioids when it 
comes to being warned of sleep-disordered breathing as a side 
effect. More reliable approaches can be designed to educate 
patients about the side effects of opioids, including sleep 
disorders and addiction,15,16 to ensure a true understanding 
of the risks and benefits of opioids. Previous studies have 
estimated the risk of sleep apnea in the chronic pain popula-
tion using opioids to be as high as 75%. The low percentages 
of patients in this survey tested and diagnosed may point to 
incomplete screening, testing, and diagnosis in this high-risk 
patient population. This large disparity between patients at 
risk and patients being diagnosed indicates that a very high 
percentage of opioid-using and non-using patients may be 
undiagnosed and untreated for sleep apnea.
We acknowledge several possible limitations to this study. 
The first limitation is that our study population was from an 
academic hospital and may not be representative of the pain 
population as a whole. Patients attending academic hospitals 
may be wealthier and better insured than the general pain pop-
ulation. Patients in this particular pain clinic were receiving 
consultation while prescribing was generally under the auspice 
of longitudinal providers such as the primary care clinicians. 
Another potential limitation of our study was the survey 
design. All information was anonymously self-reported by 
subjects and not confirmed by health records, which may lead 
to a self-report bias. Although the STOP-Bang OSA screening 
questionnaire has been validated in several populations, it has 
not been validated in the chronic pain population. This is a 
major limitation in that the STOP-Bang questionnaire, as gen-
erally applied, requires only three positive responses to define 
a high risk of OSA. In our population, many were older, over-
weight, and likely to have an increased neck circumference, 
reducing the sensitivity of the STOP-Bang score. However, 
even a comparison of STOP-Bang scores across the full range 
(from 0 to 8) did not reveal a difference in the frequency of 
OSA between opioid users and non-users. A clinician neither 
separately interviewed nor examined the subjects to confirm a 
diagnosis of sleep apnea, nor was polysomnography included 
as part of the study to validate the findings of the sleep apnea 
questionnaire. Although the STOP-Bang questionnaire has a 
relatively high sensitivity and specificity for the identification 
of OSA, polysomnography is the “gold standard” since the 
STOP-Bang questionnaire cannot identify other forms of 
sleep-disordered breathing such as CSA.
In conclusion, a large percentage of chronic pain subjects 
screened positive for OSA, regardless of opioid use. Many had 
never discussed their risk of sleep apnea with a health care 
professional nor were they personally aware that opioids may 
have increased their risk for sleep apnea. Given the estimated 
high prevalence of sleep apnea in patients on chronic opioids, 
our study indicates that a large proportion of our patients were 
undiagnosed and untreated, raising significant patient safety 
concerns. These findings suggest that physicians prescribing 
opioids need to be more conscious of the serious risks for 
sleep-disordered breathing leading to sleep apnea. There is a 
need for both greater awareness of both CSA and OSA in the 
chronic pain population and a proactive approach to provider 
discussion about sleep disorders. Education for prescribers, 
who are mostly in general medical practices, is greatly needed. 
Our initial study with the STOP-Bang questionnaire showed 
that it is simple to use and does identify patients at risk of sleep 
apnea. Future research is needed to validate a screening tool to 
properly identify those chronic pain patients at increased risk 
of sleep apnea, so that they can be appropriately tested with 
polysomnography and treated if their diagnosis is confirmed.
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